- October 6, 2023
- | CoRegen
SRC-3: CoRegen’s revolutionary approach to cancer
At the core of CoRegen’s technology is the profound understanding of SRC-3, the master regulator of the Treg genome, first discovered in the lab of renowned molecular endocrinologist Bert O’Malley at the Baylor College of Medicine.
- October 4, 2023
- | Revolo Biotherapeutics
The Mystery of My Burning Esophagus
Revolo Biotherapeutics, the company developing ‘1104, is seeking to leverage the bacterium’s ability to “reset” the immune system. If further human trials pan out, maybe we’re headed toward a new generation of drugs derived from our interactions with microbes that inhabit our bodies.
- August 16, 2023
- | Elicio Therapeutics
Vanguards of Health Care by Bloomberg Intelligence: Elicio’s Broad Cancer-Vaccine Ambitions on Apple Podcasts
Initial clinical trial data highlight the potential for a new approach to cancer vaccines to treat patients with a wide range of KRAS mutations, Elicio Therapeutics CEO Robert Connelly explains.
- August 7, 2023
- | Tessera Therapeutics
Why AbbVie’s former president has high hopes for this Flagship-backed biotech
The CEO of Tessera Therapeutics believes the company’s gene writing technology could eventually cure nearly any genetic disease across patient populations.
- August 1, 2023
- | MeiraGTx
50 OVER 50: INNOVATION
At age 50, Alexandria Forbes founded MeiraGTx, a gene therapy company with six clinical programs and innovative technology to control genes with pills. (Gene-based medicine is typically administered via the injection of cells through a vector.)
- July 31, 2023
- | Recce Pharmaceuticals
Developing Synthetic Anti-Infectives New Class of Antibiotics to Overcome Antimicrobial Resistance with James Graham Recce Pharmaceuticals
Recce Pharmaceuticals, a biotechnology company focused on the global antibiotic-resistant patient population. This new class of synthetic antibiotics takes a broad-spectrum approach to kill bacterial infections, which continue to mutate, rendering existing antibiotics ineffective. The founding inventor of Recce is Dr. Graham Melrose, the grandfather of James, who has grown this idea into one of the top-performing biotech stocks in Australia.
- July 28, 2023
- | Araris Biotech
ADC Executive Roundtable — Perfecting The Payload And Navigating The Regulatory Landscape
Philipp Spycher has an extensive background in bioconjugation and ADCs. He obtained his master’s degree and Ph.D. from ETH Zurich in material science and protein engineering. During his post-doctoral work at Paul Scherrer Institute, he introduced the novel approach of using transglutaminases for antibody conjugation, which led to the discovery of what is now called Araris linker technology.
- July 25, 2023
- | Aphaia Pharma
New weight loss drugs: biotech’s mission to end obesity
Meanwhile, Aphaia Pharma is also developing a promising drug candidate for weight loss, APH-012, with a focus on why L-cells – nutrient-sensing cells in the distal part of the intestine – in patients with metabolic disease are largely deprived from contact with food, as this leads to a lack of endocrine, neuroendocrine, and neuronal stim